GlassScriptPhysician profile
Mark B Alrais
NPI 1083875702
$5,821.76
in general payments reported to CMS, 2019-2025
48 companies · $556 in 2025
The $556 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $663 · 2021: $1,025 · 2022: $1,394 · 2023: $959 · 2024: $862 · 2025: $556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $864.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $648.30 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $607.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $486.09 | 2021-2024 | Qulipta, Vraylar |
| Pfizer INC. | $478.71 | 2019-2025 | |
| Horizon Therapeutics Plc | $288.05 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $235.70 | 2019-2024 | |
| Exact Sciences Corporation | $167.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $166.43 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Upsher-Smith Laboratories LLC | $148.52 | 2020-2023 | |
| Amarin Pharma, INC. | $142.91 | 2019-2022 | |
| Abbott Laboratories | $112.60 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $107.24 | 2022 | |
| Astellas Pharma US INC | $96.65 | 2020-2024 | Veozah, Myrbetriq |
| Nevro Corp. | $96.10 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Alrais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.